Hemophilia A is a congenital bleeding disorder caused by a deficiency of coagulation factor VIII. Approximately 30% of hemophilia A patients develop inhibitors against FVIII following replacement therapy. We have reported that neonatal exposure of FVIII antigen can induce antigen-specific immune tolerance by interferon-gamma (IFN-gamma)-dependent T-cell anergy in hemophilia A mice.
Research Division of Cell and Molecular Medicine, Centre for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan. madochan@jichi.ac.jp